Luminary Group’s Post

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> ArriVent prices $175M IPO in back-to-back oncology biotech listings: ArriVent BioPharma will join the Nasdaq on Friday morning in a strong start to biotech’s first batch of initial public offerings this year. The Pennsylvania drugmaker said Thursday night it would sell 9.72 million shares $AVBP at $18 apiece, the midpoint of the range it proposed earlier this week. The late-stage biotech will raise $175 million in its upsized offering. The listing comes a day after the first biotech IPO of the year, in which Phase III bladder cancer drugmaker CG Oncology drew in $380 million. CG will be a tough act to follow: The California biotech saw its stock price $CGON skyrocket 95% on its first day of trading, rising from $19 to $37 after investor demand caused its stock to start trading hours later than expected. But like CG, ArriVent is also in Phase III testing for its lead asset: furmonertinib. The market has favored late-stage assets in recent quarters as many investors were burned by the wave of preclinical platform biotechs that went public at a record pace during the 2020 and 2021 bull rush. ArriVent’s EGFR-targeted tyrosine kinase inhibitor is already approved in China and marketed by Allist Pharmaceuticals. ArriVent has a licensing deal for the asset and anticipates having pivotal data in 2025. It’s testing furmonertinib as a first-line therapy for patients with EGFRm non-small cell lung cancer involving exon 20 insertion mutations. The company also has an asset in the red-hot field of antibody-drug conjugates and plans to have a clinical candidate by year’s end or early 2025, per its SEC paperwork. A few more private biotechs are expected to price their listings soon, including autoimmune CAR-T maker Kyverna, CNS drugmaker Alto Neuroscience, obesity biotech Fractyl Health and preclinical gene editing company Metagenomi. Industry insiders anticipate more IPO filings to come in before the spring, as well. The largest shareholders in ArriVent are Hillhouse Investment Management at 17.6% and OrbiMed at 11.6%. Other backers include LAV Fund VI, Octagon Capital Advisors, Allist, Sofinnova Venture Partners and Sirona Capital Partners. #lucidquest #genetherapy #celltherapy

Initial Biotech IPO's are off to a great start in 2024! ...ArriVent Biopharma will join the Nasdaq on Friday morning in a strong start to biotech’s first batch of initial public offerings this year.... ...The listing comes a day after the first biotech IPO of the year, in which Phase III bladder cancer drugmaker CG Oncology drew in $380 million.... ...A few more private biotechs are expected to price their listings soon, including autoimmune CAR-T maker Kyverna Therapeutics, CNS drugmaker Alto Neuroscience, obesity biotech Fractyl Health and preclinical gene editing company Metagenomi. Industry insiders anticipate more IPO filings to come in before the spring, as well.... #IPO #publicmarkets #oncology #biotech #biotechnology #therapeutics #celltherapy #cellandgenetherapy #geneediting #cartcell #cartcelltherapy #CNS #obesity #pharmaceuticals #lifesciences #healthcare #biopharma #biopharmaceuticals #financing #380m #advancedtherapies #regenerativemedicine Zhengbin (Bing) Yao

Sutro Biopharma's success stems from innovative work in antibody-drug conjugates (ADCs), a #cuttingedge approach to cancer treatment. Their financial growth is equally impressive, driven by strategic partnerships and promising results from #drugtrials. For investors in the biotech sector, this demonstrates the potential for significant advancements and profitability within #biotech. What do you all think—are the analysts right to be bullish on Sutro? https://loom.ly/AELSaWk

Iambic Therapeutics announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was funded by new investors Mubadala Capital, Exor Ventures and the Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Ventures, Coatue, and Tao Capital. The extension adds to an oversubscribed $100 million Series B that closed in October and was co-led by Ascenta Capital and Abingworth, joined by NVIDIA and others.    Iambic Therapeutics' physics-informed AI-driven discovery platform has enabled a pipeline of novel small molecule therapeutics, including IAM1363, a highly selective, brain-penetrant inhibitor of wild-type and oncogenic mutant HER2 proteins currently in Phase 1 studies, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor. Proceeds from a combined >$150M Series B financing will be used to broaden and accelerate Iambic's clinical and pre-clinical oncology programs.    Ron Mazumder Charles Lin Bill Rastetter     Read the full press release: https://lnkd.in/eQk6jD96    This news follows another exciting announcement earlier that Thomas Miller, CEO of Iambic Therapeutics, has received the EY Entrepreneur Of The Year® 2024 Pacific Southwest Award. See EY’s full press release here: https://lnkd.in/eUShge_T Way to go, Tom!    #partnernews #SeriesB #biotech #lifescience #MachineLearning #AI #DrugDiscovery #healthcare

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

𝐀𝐫𝐫𝐢𝐕𝐞𝐧𝐭 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐢𝐜𝐞𝐧𝐬𝐞𝐬 𝐍𝐨𝐯𝐞𝐥 𝐀𝐃𝐂 𝐟𝐫𝐨𝐦 𝐀𝐚𝐫𝐯𝐢𝐤 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 After a significant collaboration that began with a $100 million deal in December 2021, ArriVent BioPharma is now officially licensing an innovative antibody-drug conjugate (ADC) from Aarvik Therapeutics. 𝐊𝐞𝐲 𝐃𝐞𝐭𝐚𝐢𝐥𝐬: • Aarvik was responsible for the discovery and preclinical development, while ArriVent was set to take over at the human trials stage. • Though the exact upfront payment was not disclosed, Aarvik stands to gain up to $100 million, including research funding, option fees, milestone payments, and potential royalties. • The drug, based on Aarvik’s unique modular platform, is a next-generation ADC designed to advance oncology treatments. “Our advanced protein engineering technologies and ADC drug development expertise are paving the way for next-generation, best-in-class oncology therapies,” said Jagath Reddy Junutula, Ph.D., CEO and co-founder of Aarvik. ArriVent also recently 𝐫𝐚𝐢𝐬𝐞𝐝 $175 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐚𝐧 𝐈𝐏𝐎 and remains focused on bringing innovative drugs from China to Western markets, including securing rights to Allist Pharmaceuticals' EGFR tyrosine kinase inhibitor furmonertinib in 2021. Stay tuned for the updates on this collaboration. #Biotech #Oncology #ADC #DrugDevelopment #PharmaNews

2024 is shaping up to be a busy year for biopharma IPOs: Seven companies in the sector have already IPO’d since the start of the year, for a collective exit value of $3.1 billion. The largest of the lot, California-based CG Oncology, raised nearly $400 million in its Nasdaq IPO in January to fund the development of bladder cancer treatments. The upswell in IPOs has the potential to drive more drug companies to explore a public listing, according to PitchBook’s Q4 2023 Biopharma Report. In the private markets, biotech startups are riding the AI wave in drug discovery to harness large datasets: Insitro, Valo and Tessera Therapeutics are among those deploying machine learning for drug development.

Takeda inks sweet $1.2B+ deal with Kumquat for immuno-oncology program: Takeda has offered Kumquat Biosciences the chance to make more than $1.2 billion in a new exclusive pact that centres around an immune-oncology small molecule inhibitor. After running phase 1 trial activities Kumquat can grant Takeda global licensing rights to develop and commercialise the asset. Big Pharma Takeda will then take responsibility for all development and commercialisation activities following phase 1. Subsequently a selected program can be developed as a monotherapy, combo therapy or both. Kumquat is set to make up to $130 million in near-term payments, with additional chance to grab $1.2 billion in future clinical, regulatory and commercial milestones. Share your thoughts on the collaboration: #takeda #oncology #kumquat #biosciences #licensingdeals

🚀 Now Available: Degrader-Antibody Conjugates 2024 Report 🚀 We are excited to announce the release of a comprehensive new report, “Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline, and Partnering from an Industry Perspective.” This cutting-edge analysis explores the rapidly evolving field of Degrader-Antibody Conjugates (DACs), combining the strengths of antibody-drug conjugation and targeted protein degradation (TPD) technologies. We have summarized the report offering in our latest blog: https://lnkd.in/dmbBXdDf 🔍 What’s Inside: In-depth profiles of industry stakeholders: Bristol Myers Squibb, C4 Therapeutics, Inc., Crossfire Oncology, Cullgen Inc., Debiopharm, Eisai US and others. Overview of platform technologies like PROTAC and molecular glue A look into the clinical and non-clinical development pipeline Details on partnership activities, acquisitions, licensing, and collaborations Whether you're a biotech innovator, pharma leader, or investor, this report offers crucial insights into the future of precision medicine and targeted therapies. 📖 Available now at MarketResearchReports.com. Don't miss out on the opportunity to stay ahead in this exciting new field!

More moving and 'shaking' in the #OncologyDevelopment space: So soon after Merck inked their own deal, the MA biotech C4 Therapeutics, Inc. signs another with Merck KGaA, Darmstadt, Germany to seek out two #ProteinDegraders. #Oncology #MerckKGaA #Biotech #Innovation #Licensing #Pharma #Healthcare